Emerging Markets

June 2013

Non-Small-Cell Lung Cancer in Turkey

Report Authors
Natalia Reoutova, M.A., M.Sc.
Anouchka Seesaghur, M.B.B.S., M.P.H.

Introduction:

The Turkish NSCLC market will grow at a rate of 7% per year between 2012 and 2017, and the number of NSCLC incident cases will grow by nearly 30% between 2012 and 2022. Changing medical practice, growing NSCLC population, and persistent use of branded agents offer significant opportunity to multinational companies (MNCs) with emerging therapies in this indication. In this report, we examine the trends within Turkey’s NSCLC pharmaceutical market, which is characterized by the growing use of targeted therapies, changes in reimbursement policy, the introduction of several new agents, and the Turkish government’s stringent price controls.

Questions Answered in This Report:

  *   Between 2012-2017, eight new therapies are expected to enter Turkey’s NSCLC market. Will they be new entrants to the existing drug classes or will they feature novel mechanisms of action? How widely will these agents be used in Turkey, in which histological subtypes and lines of treatment? What are Turkish oncologists’ perceptions of the emerging therapies?

  *   Pricing of therapies and reimbursement policies in the public sector are major factors influencing expenditure on NSCLC treatments in Turkey. How does the pricing of branded and generic agents used in treatment of NSCLC differ between Turkey and the major markets? Which groups of Turkish patients are eligible for government-reimbursed treatment of NSCLC? Which therapies are currently not readily available to the Turkish patients, and is it likely that the patient shares of those agents will increase substantially in the next several years?

  *   The Turkish NSCLC market will grow at 7% annually between 2012 and 2017. What was the size of the Turkish NSCLC market in 2012? How large will the market be in 2017? What factors will drive growth in this market? What factors will constrain it?

  *   The number of incident cases of NSCLC in Turkey will increase by nearly 30% between 2012 and 2022. What was the number of incident cases of NSCLC in Turkey in 2012? How many of them were male? How were the cases distributed between histological subtypes and stages of disease? What will be the main causes for incident population growth?

Scope:

Primary research: 73 oncologists surveyed across Turkey. Separate in-depth interviews with 8 Turkish oncologists.

Epidemiology: Total incident cases of NSCLC in Turkey over a ten-year period (2012-2022) by age, stage, gender, and histology.

Current therapies and medical practice: Reporting use of brands and generics for the NSCLC treatments available in Turkey.

Pricing and reimbursement: Prices of NSCLC therapies in Turkey versus other major markets and analysis of the impact of government reimbursement on treatment trends.

Market forecast features: Our analysis evaluates rates of NSCLC progression and rates of drug treatment with NSCLC therapies, across all stages of the disease. We include a detailed forecast of current and emerging therapies within platinum agents, antitubulins, antimetabolites, other cytotoxic agents, EGFR inhibitors, angiogenesis inhibitors, ALK inhibitors, immunotherapies, and c-Met inhibitors from 2012 through 2017, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - Boehringer Ingelheim
  • - Bristol-Myers Squibb
  • - Celgene
  • - Eisai
  • - Eli Lilly
  • - Koçak Farma
  • - Novartis
  • - Pfizer
  • - Pierre Fabre
  • - Roche
  • - Sanofi
Decision Resources Group brands include: